Intarcia 'on cloud nine' after $210m private funding for once-yearly exenatide implant

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Intarcia Therapeutics raised a whopping $210 million in private financing in concurrent transactions to fund Phase III development of its type 2 diabetes product candidate ITCA 650, which consists of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide delivered continuously by a matchstick-sized, subcutaneously-implanted osmotic pump.

Intarcia Therapeutics raised a whopping $210 million in private financing in concurrent transactions to fund Phase III development of its type 2 diabetes product candidate ITCA 650, which consists of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide delivered continuously by a matchstick-sized, subcutaneously-implanted osmotic pump.

The Hayward, California-based company's $160 million preferred stock private placement and $50 million private debt placement comprise the largest sum...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Alimentary/Metabolic

ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

 
• By Jung Won Shin

The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

 
• By Xu Hu

Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 
• By Andrew McConaghie

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.